Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jay Lee

Thoracic Surgery (Cardiothoracic Vascular Surgery) Los Angeles, CA Medical Doctor

NPI 1952326654 CMS profile 1073446

200 Ucla Medical Plz Ste B265, Los Angeles, CA 90095

Open in the dashboard

General payments

$462,144

330 records reported · program years 2019–2025

Research payments

$70,122

Paid to them · 40 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$394,011 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Jay Lee of Los Angeles, CA is reported in the CMS Open Payments database as having received $462,144 across 330 general payments and $70,122 in research payments paid to them. Separately, studies naming them as principal investigator received $394,011 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $166,506 93
2025 Research $557 2
2024 General $107,113 80
2024 Research $4,506 3
2023 General $79,105 70
2023 Research $13,840 8
2022 General $43,462 39
2022 Research $34,820 13
2021 General $32,998 15
2021 Research $13,604 10
2020 General $16,757 12
2020 Research $2,796 4
2019 General $16,202 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jay Lee
  • Thoracic Surgery (Cardiothoracic Vascular Surgery) median
  • Middle half of Thoracic Surgery (Cardiothoracic Vascular Surgery)
  • National median

In program year 2025, general payments to Jay Lee were reported at $166,506. Among 4,073 Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles paid that year, the median was $791 and the middle half received between $208 and $3,074.

Show as a table
Year Jay Lee Thoracic Surgery (Cardiothoracic Vascular Surgery) median Middle half National median
2019 $16,202 $886 $178–$3,167 $163
2020 $16,757 $341 $108–$1,605 $114
2021 $32,998 $453 $125–$1,886 $132
2022 $43,462 $695 $180–$2,566 $149
2023 $79,105 $745 $205–$2,662 $160
2024 $107,113 $799 $214–$2,967 $164
2025 $166,506 $791 $208–$3,074 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $179,784 93 payments
  2. AstraZeneca Pharmaceuticals LP $74,038 66 payments
  3. Regeneron Pharmaceuticals, Inc. $58,181 61 payments
  4. Genentech, Inc. $31,739 18 payments
  5. Genentech USA, Inc. $29,989 26 payments
  6. E.R. Squibb & Sons, L.L.C. $29,779 21 payments
  7. Novartis Pharmaceuticals Corporation $21,871 12 payments
  8. F. Hoffmann-La Roche AG $16,043 12 payments
  9. Eli Lilly and Company $8,000 5 payments
  10. AbbVie, Inc. $6,659 4 payments
  11. Other $6,063 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $254,065 97 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $113,824 20 payments
  3. Travel and Lodging $86,312 98 payments
  4. Food and Beverage $7,944 115 payments
Products named General payments · program years 2019–2025
  1. LIBTAYO $52,941 55 payments
  2. TECENTRIQ $51,517 35 payments
  3. IMFINZI $27,117 25 payments
  4. TAGRISSO $24,618 17 payments
  5. OPDIVO $16,606 8 payments
  6. KEYTRUDA $16,343 15 payments
  7. TABRECTA $9,833 3 payments
  8. Alecensa $9,179 8 payments
  9. ILARIS Immunology $5,197 4 payments
  10. ILARIS Immunology $4,271 3 payments
  11. Other $7,484 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Genentech, Inc. $29,648 9 payments
  2. F. Hoffmann-La Roche AG $23,935 25 payments
  3. Novartis Pharmaceuticals Corporation $10,045 3 payments
  4. Novartis Pharma AG $6,495 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

14

Median for Thoracic Surgery: 42

Drug cost

$73

Median for Thoracic Surgery: $318

Branded share of claims

0%

Median for Thoracic Surgery: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 14 $73

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 910 Part D prescribers listed as Thoracic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$177,074

Medicare's payments for the services billed

Medicare patients

239

Average age 73

Services billed

684

133 women, 106 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 75%
Arthritis 55%
Ischemic heart disease 48%
COPD 38%
Diabetes 30%
Osteoporosis 29%
Atrial fibrillation 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LIBTAYO
  • Regeneron Pharmaceuticals, Inc. $18,508
$18,508 — —
Alecensa
  • Genentech USA, Inc. $2,642
  • F. Hoffmann-La Roche AG $1,409
$4,051 — —
TECENTRIQ
  • F. Hoffmann-La Roche AG $1,409
$1,409 — —
IMFINZI
  • AstraZeneca Pharmaceuticals LP $964
$964 — —
TAGRISSO
  • AstraZeneca Pharmaceuticals LP $92
$92 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

370 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Thoracic Surgery (Cardiothoracic Vascular Surgery) in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record